Crossject SA — SEC Form D Filing

Crossject SA filed an SEC Form D on June 5, 2026, reporting $10.26M raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
June 5, 2026
Amount reported
$10.26M
Round stage
Seed
Industry
Pharmaceuticals
Website
https://crossject.com/en/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: FRANCE

Problem

People with epilepsy, adrenal crisis, and anaphylaxis often face life-threatening situations where current treatments may be inadequate, such as refractory seizures in epilepsy patients and the need for immediate emergency treatment for anaphylaxis.

Solution

Crossject offers ZENEO®, a needle-free, pre-filled, single-use auto-injector intended for rapid delivery of emergency medications in critical situations, addressing issues with existing treatments by ensuring fast and safe administration.

Why now

The increasing prevalence of life-threatening emergencies requires innovative solutions for faster drug delivery.

Verdict

Investors supported Crossject at this moment because the growing demand for immediate emergency responses legitimized the need for needle-free technology, not because existing solutions demonstrated overwhelming efficacy or reliability. Their implicit bet was on the expectation that healthcare providers would swiftly adopt ZENEO® for its potential to improve patient outcomes during critical situations. However, the limited upside is tied to a crowded market of alternatives where differentiation might wane, and long-term adoption hinges on proving superior efficacy over traditional methods.

Source: SEC EDGAR Form D filing